[1] 何庭艳, 杨军.白塞病诊治进展[J].中国实用儿科杂志, 2020, 35(4):284-288.
[2] Ishibashi H.What is vascular Behçet's disease?[J].Ann Vasc Dis, 2018, 11(1):52-56.
[3] Coilly A, Potier P, Broué P, et al.Budd-Chiari syndrome[J].Clin Res Hepatol Gastroenterol, 2020, 44(4):420-425.
[4] International Study Group for Behçet's Disease.Criteria for diagnosis of Behçet's disease[J].Lancet, 1990,335(8697):1078-1080.
[5] International Team for the Revision of the International Criteria for Behçet's Disease(ITR-ICBD).The International Criteria for Behçet’s Disease (ICBD):a collaborative study of 27 countries on the sensitivity and specificity of the new criteria[J].J Eur Acad Dermatol Venereol, 2014, 8(3):338-347.
[6] Desbois A C, Wechsler B, Resche-Rigon M, et al.Immunosuppressants reduce venous thrombosis relapse in Behçet's disease[J].Arthritis Rheum, 2012, 64(8):2753-2760.
[7] Ben Ghorbel I, Ennaifer R, Lamloum M, et al.Budd-Chiari syndrome associated with Behçet's disease[J].Gastroenterol Clin Biol, 2008, 32(3):316-320.
[8] Emmi G, Bettiol A, Silvestri E, et al.Vascular Behçet's syndrome:an update[J].Intern Emerg Med, 2019, 14(5):645-652.
[9] Jayachandran N V, Rajasekhar L, Chandrasekhara P K, et al.Multiple peripheral arterial and aortic aneurysms in Behcet's syndrome:a case report[J].Clin Rheumatol, 2008, 27(2):265-267.
[10] Tascilar K, Melikoglu M, Ugurlu S, et al.Vascular involvement in Behçet's syndrome:a retrospective analysis of associations and the time course[J].Rheumatology (Oxford), 2014, 53(11):2018-2022.
[11] Valla D C.Budd-Chiari syndrome/hepatic venous outflow tract obstruction[J].Hepatol Int, 2018, 12(Suppl 1):168-180.
[12] Khan F, Armstrong M J, Mehrzad H, et al.Review article:a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome[J].Aliment Pharmacol Ther, 2019, 49(7):840-863.
[13] Sakr M A, Reda M A, Ebada H E, et al.Characteristics and outcome of primary Budd-Chiari syndrome due to Behçet's syndrome[J].Clin Res Hepatol Gastroenterol, 2020, 44(4):503-512.
[14] Desbois A C, Rautou P E, Biard L, et al.Behcet's disease in Budd-Chiari syndrome[J].Orphanet J Rare Di, 2014, 9:104.
[15] Uskudar O, Akdogan M, Sasmaz N, et al.Etiology and portal vein thrombosis in Budd-Chiari syndrome[J].World J Gastroenterol, 2008, 14(18):2858-2862.
[16] Harmanci O, Kav T, Peynircioglu B, et al.Long-term follow-up study in Budd-Chiari syndrome:single-center experience in 22 years[J].J Clin Gastroentero, 2013, 47(8):706-712.
[17] Cansu D U, Temel T, Erturk A, et al.The long-term outcomes for patients with budd-chiari syndrome caused by behcet?s disease:a case series on the results, from cirrhosis to death[J].Hepat Mon, 2016, 16(10):e32457.
[18] Hatemi G, Christensen R, Bang D, et al.2018 update of the EULAR recommendations for the management of Behçet's syndrome[J].Ann Rheum Dis, 2018, 77(6):808-818.
[19] Santos L B, Rigueira J, Vilas A P.Infliximab in the treatment of Budd-Chiari syndrome in Behçet's disease[J].Reumatismo, 2019, 71(3):163-165.
[20] Hatemi G, Seyahi E, Fresko I, et al.One year in review 2019:Behçet's syndrome[J].Clin Exp Rheumatol, 2019, 37(Suppl 6):S121.
[21] Alibaz-Oner F, Karadeniz A, Ylmaz S, et al.Behçet's disease with vascular involvement:effects of different therapeutic regimens on the incidence of new relapses[J].Medicine (Baltimore), 2015, 94(6):e494.
[22] Merashli M, Eid R E, Uthman I.A review of current management of vasculo-Behcet's[J].Curr Opin Rheumatol, 2018, 30(1):50-56.
[23] Hamzaoui A, Fatima J, Thouraya B S, et al.Vena cava thrombosis in Behçet's disease[J].Anadolu Kardiyol Derg, 2014, 14(3):292-293.
[24] Bittencourt Mde J, Dias C M, Lage T L, et al.Behçet's disease in association with Budd-Chiari syndrome and multiple thrombosis-case report[J].An Bras Dermatol, 2013, 88(3):448-451. |
